STOCK TITAN

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Cannabix Technologies Inc. is collaborating with Breathalyser Sales & Service Pty in Australia to distribute its new Breath Logix Alcohol screening device. This device offers features like pre-calibrated cartridge technology, automatic BAC level detection, and real-time alerts for users in various sectors. Cannabix aims to provide an innovative solution for alcohol screening in workplaces and other settings.

Cannabix Technologies Inc. sta collaborando con Breathalyser Sales & Service Pty in Australia per distribuire il suo nuovo dispositivo di rilevamento dell'alcool Breath Logix. Questo dispositivo offre caratteristiche come la tecnologia di cartucce pre-calibrate, la rilevazione automatica del livello di alcolemia (BAC) e avvisi in tempo reale per gli utenti in vari settori. Cannabix mira a fornire una soluzione innovativa per il controllo dell'alcool nei luoghi di lavoro e in altri ambienti.
Cannabix Technologies Inc. está colaborando con Breathalyser Sales & Service Pty en Australia para distribuir su nuevo dispositivo de detección de alcohol Breath Logix. Este dispositivo incluye características como tecnología de cartuchos pre-calibrados, detección automática del nivel de alcohol en sangre (BAC) y alertas en tiempo real para usuarios en diversos sectores. Cannabix tiene como objetivo proporcionar una solución innovadora para el control del alcohol en lugares de trabajo y otros entornos.
Cannabix Technologies Inc.는 호주의 Breathalyser Sales & Service Pty와 협력하여 새로운 Breath Logix 알코올 스크리닝 장치를 배포하고 있습니다. 이 장치는 사전 교정된 카트리지 기술, 자동 BAC 레벨 감지 및 다양한 부문의 사용자를 위한 실시간 알림과 같은 기능을 제공합니다. Cannabix는 직장 및 기타 환경에서 알코올 스크리닝을 위한 혁신적인 솔루션을 제공하고자 합니다.
Cannabix Technologies Inc. collabore avec Breathalyser Sales & Service Pty en Australie pour distribuer son nouvel appareil de dépistage d'alcool Breath Logix. Cet appareil propose des fonctionnalités telles que la technologie de cartouche pré-calibrée, la détection automatique du taux d'alcoolémie (BAC) et des alertes en temps réel pour les utilisateurs dans divers secteurs. Cannabix vise à fournir une solution innovante pour le dépistage de l'alcool sur les lieux de travail et dans d'autres cadres.
Cannabix Technologies Inc. arbeitet mit Breathalyser Sales & Service Pty in Australien zusammen, um sein neues Breath Logix Alkohol-Screening-Gerät zu vertreiben. Das Gerät verfügt über Funktionen wie vorab kalibrierte Kartuschentechnologie, automatische BAC-Level-Erkennung und Echtzeitwarnungen für Benutzer in verschiedenen Bereichen. Cannabix zielt darauf ab, eine innovative Lösung für das Alkoholscreening in Arbeitsumgebungen und anderen Bereichen bereitzustellen.
Positive
  • Cannabix Technologies Inc. is expanding its market reach by partnering with Breathalyser Sales & Service Pty in Australia for the distribution of its Breath Logix Alcohol screening device.

  • The Breath Logix Industrial Series device offers a range of features including patent pending pre-calibrated cartridge technology, automatic BAC level detection, and real-time alerts for users.

  • The device is designed for various testing purposes such as pre-access, random, start-of-shift, pre-employment, return-to-work, and post-incident testing, catering to a wide range of industries.

Negative
  • There is no guarantee that the evaluators of Cannabix's breathalyzer technology will finalize a distribution agreement or sales deal with the Company, posing a potential risk to the business.

Cannabix is developing alcohol and marijuana breathalyzer devices to give law enforcement and employers a tool to enhance public safety

VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of alcohol and marijuana breathalyzer screening devices for law enforcement and the workplace reports that it has commenced discussions with Breathalyser Sales & Service Pty Ltd. of Sydney, Australia (“Breathalyser SSP”) for the sales distribution of the Company’s Breath Logix Alcohol screening device (see Figure 1). Breathalyser SSP is a leading distributor of alcohol and drug testing devices for employers and personal use, offering well established alcohol product lines like Draeger and AlcoMeasure for the Australian market with regional offices in Perth, Melbourne and Brisbane. Breathalyser SSP has clients in a range of sectors including mining, oil and gas, industrial, trucking, warehousing and technology. Cannabix will be shipping its Breath Logix Industrial Series device to Breathalyser SSP for evaluation, preliminary marketing and business development purposes.

Ben Smit, Managing Director of Breathalyser Sales & Service Pty Ltd., stated, “We have been impressed with the Cannabix team’s ability to develop the Breath Logix wall mounted device over the last several months. Breathalyser Sales and Service is Australia's oldest distributor and leader in the supply, service & calibration of drug and alcohol testing equipment. We see the Breath Logix Industrial Series fitting into the Australian marketplace well due to is rugged exterior, ease of use and unique cartridge technology. Autonomous employee alcohol screening is a major segment of our business and we welcome innovative products like the Breath Logix device.”

Figure 1. Breath Logix Industrial Series device

Figure 1. Breath Logix Industrial Series device

Breath Logix Industrial Series Features

The Breath Logix Industrial Series is a weather resistant device with a host of requested features including patent pending pre-calibrated cartridge technology which will allow site safety administrators to easily maintain their devices, and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance. This device can be used for pre-access alcohol testing, random testing, start-of-shift testing, pre-employment testing, return-to-work testing and post-incident testing. The device is currently being piloted as a solution for the 24/7 sobriety program which exists in several states.

The Breath Logix Alcohol device automatically checks the sobriety of a user and can take a picture to confirm and record identity while a breath sample is being delivered. Upon detection of positive breath alcohol result, the device will deliver a precise Blood Alcohol Content (BAC) level on the screen, and send a real-time alert via text message, e-mail and to a dedicated web portal. Furthermore, the system logs user BAC for incident reporting and historical investigations. The Breath Logix helps organizations save money by deploying an autonomous alcohol screening device which eliminates the need for dedicated alcohol screening administrators using conventional handheld devices. There is no assurance that evaluators of the Company’s breathalyzer technology will come to terms on distribution or enter into a sales agreement with the Company.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of Breath Logix Series of autonomous breath alcohol detection devices for employers and a range of other settings.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that its development of breathalyzer technology will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. There is no assurance that evaluators of the Company’s breathalyzer technology will agree or come to terms on distribution or enter into a sales agreement, of any kind. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9a70ac03-45e6-454a-bd18-ff1e61e6ff60.


FAQ

What is Cannabix Technologies Inc. collaborating on with Breathalyser Sales & Service Pty ?

Cannabix Technologies Inc. is collaborating with Breathalyser Sales & Service Pty in Australia for the distribution of its Breath Logix Alcohol screening device.

What are some features of the Breath Logix Industrial Series device?

The Breath Logix Industrial Series device offers features like pre-calibrated cartridge technology, automatic BAC level detection, and real-time alerts for users.

What testing purposes is the Breath Logix Industrial Series device designed for?

The device is designed for various testing purposes such as pre-access, random, start-of-shift, pre-employment, return-to-work, and post-incident testing, catering to a wide range of industries.

Is there any potential risk associated with the collaboration between Cannabix and Breathalyser SSP?

There is no guarantee that the evaluators of Cannabix's breathalyzer technology will finalize a distribution agreement or sales deal with the Company, posing a potential risk to the business.

CANNABIX TECHS INC ORD

OTC:BLOZF

BLOZF Rankings

BLOZF Latest News

BLOZF Stock Data

39.19M
105.55M
8.33%
0.01%
Medical Devices
Healthcare
Link
United States of America
Burnaby